Journal

The EU has delayed full AI Act application for high-risk medical AI by 12 months. The delay does not make regulation less important — it gives serious companies more time to build ...

AI scribes will not remain scribes. They are moving into coding, referrals, safety-netting, and follow-up — where documentation ends and decision support begins. That boundary matt...

NHS England has published specific guidance for AI ambient scribing products — covering consent, transparency, information governance, clinical safety, and EHR integration. Here is...

UK general practice is under operational pressure, but it is also one of the most structured, digitally mature primary care markets in Europe. Doctolib's Medicus acquisition sugges...

The old GP IT market was stable because switching was painful. Now, NHS England reforms, cloud EPRs, AI assistants, and international capital are pushing against that inertia. Doct...

Clinical AI tools now report large query and consultation volumes. But clinicians should evaluate adoption claims alongside active use, source quality, jurisdictional relevance, ci...

OpenEvidence proved that doctors want fast, cited medical answers. Now Europe is developing its own clinical AI search market, shaped by local guidelines, regulation, and workflow.

Praxis Medicine, OpenEvidence, and iatroX all sit near the clinical AI search category, but they differ by geography, workflow, source strategy, and intended users.

AI scribes save time on documentation. Clinical AI search helps doctors retrieve evidence, guidelines and medical knowledge. The next market will be about which workflow earns dail...

A practical guide to AI medical search tools for UK clinicians, including iatroX, Praxis Medicine, Medwise, AMBOSS AI Mode, OpenEvidence and other evidence-search platforms.

DR.INFO offers an evidence-first medical AI API. This reflects a wider shift from standalone medical chatbots to clinical information infrastructure.

DR.INFO's CE-marked positioning shows how European clinical AI is moving toward regulation, source references, and professional-use boundaries.